Guggenheim Capital LLC Catalyst Pharmaceuticals, Inc. Transaction History
Guggenheim Capital LLC
- $14 Billion
- Q3 2024
A detailed history of Guggenheim Capital LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 24,760 shares of CPRX stock, worth $535,311. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,760
Previous 54,129
54.26%
Holding current value
$535,311
Previous $838,000
41.29%
% of portfolio
0.0%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding CPRX
# of Institutions
326Shares Held
94MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$404 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$174 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$135 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$123 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$65.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.22B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...